ClinicalTrials.gg
CompletedNCT02159066LOGIC-2Updated Mar 5, 2024Results posted

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

A Phase 2 interventional study of LGX818 and MEK162 in Melanoma, sponsored by Pfizer. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing encorafenib in Melanoma — 4 open to participants now, 8 under way, 2 of them phase 3. encorafenib · Melanoma.

Enrollment
5th of 27
158 · median 35
Started
2014
the only one that year
Phase 2
14 of 27
3 open now
Registered
6th of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing encorafenib in Melanoma, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 14 in phase 2, and was the 6th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 27 studies testing encorafenib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing encorafenib in Melanoma, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Read the detailed description

This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter Part II of the study for tailored combination treatment in one of four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled directly in Part II of CLGX818X2109 after relapse.

Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA:

  • Age ≥ 18 years
  • confirmed diagnosis of unresectable stage III or melanoma (stage IIIC to IV per American Joint Committee on Cancer [AJCC])
  • Documented evidence of BRAF V600 mutation.
  • Newly obtained tumor at baseline, and patient agrees to a mandatory biopsy at the time of progression, if not medically .
  • Evidence of , as determined by v1.1.

INCLUSION CRITERIA for triple combinations:

Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL EXCLUSION CRITERIA Symptomatic or untreated .

  • Symptomatic . Patients previously treated or untreated for brain metastases that are asymptomatic in the absence of therapy or on a stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs.
  • Patients who have developed brain metastases during Part I of the study may continue to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be either asymptomatic or treated and stable for at least 4 weeks and on a stable or tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not eligible for the combination with LEE011.
  • Known acute or chronic pancreatitis.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
  • cardiac disease including any of the following:
  • CHF requiring treatment (NYH grade ≥ 2),
  • \< 50% as determined by MUGA scan or ECHO
  • History or presence of clinically significant ventricular arrhythmias or atrial fibrillation
  • Clinically significant resting bradycardia
  • Unstable angina pectoris ≤ 3 months prior to starting study drug
  • Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug,
  • > 480 msec. Patients with any of the following laboratory values at

Screening/baseline:

  • (ANC) \<1,500/mm3 [1.5 x 109/L]
  • \< 100,000/mm3 [100 x 109/L]
  • \< 9.0 g/dL
  • Serum creatinine >1.5 x or calculated or directly measured \< 50% LLN (lower limit of normal)
  • Serum total >1.5 x ULN
  • /SGOT or ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present

Additional exclusion criteria for the triple combinations:

LGX818/MEK162/BKM120:

  • Patients with fasting glucose > 120 mg/dL or 6.7 mmol/L, and > 8 %.
  • Patient has any of the following mood disorders as judged by the

Investigator or a Psychiatrist:

  • Patient has a score ≥ 12 on the PHQ-9 questionnaire
  • Patient has ≥ grade 3 anxiety

LGX818/MEK162/BGJ398:

  • History and/or current evidence of significant ectopic mineralization/ calcification with the exception of calcified lymph nodes and asymptomatic vascular calcification.
  • Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/ band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits etc., confirmed by ophthalmologic examination

LGX818/MEK162/LEE011:

  • Patients with uncontrolled hypertension (please refer to WHO-ISHguidelines) are excluded from study.
  • QTcF >450 ms for males and >470 ms for females Congenital long QT syndrome or family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 and magnesium levels below the clinically relevant lower limits at study entry
  • Current evidence of brain metastasis or brain metastasis detected by mandatory CT/MRI at screening
  • or aPTT > 1.5xULN

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    LGX818 + MEK162

    Drug: LGX818 · Drug: MEK162

  • Experimental
    LGX818 + MEK162 + LEE011

    Drug: LEE011

  • Experimental
    LGX818 + MEK162 + BGJ398

    Drug: BGJ398

  • Experimental
    LGX818 + MEK162 + BKM120

    Drug: BKM120

  • Experimental
    LGX818 + MEK162 + INC280

    Drug: INC280

Interventions

  • DrugLGX818

    Combination of LGX818 and MEK162 (Part I)

  • DrugMEK162

    Combination of LGX818 and MEK162 (Part I)

  • DrugLEE011

    Combination of LGX818 + MEK162 + LEE011 (Part II)

  • DrugBGJ398

    Combination of LGX818 + MEK162 + BGJ398 (Part II)

  • DrugBKM120

    Combination of LGX818 + MEK162 + BKM120 (Part II)

  • DrugINC280

    Combination of LGX818 + MEK162 + INC280 (Part II)

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR): Part II

    ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.

    Time frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II

    DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.

    Time frame: Cycle 1 (21 days following the first dose of the combination treatment with buparlisib and capmatinib; 28 days for the combination with ribociclib and infigratinib)

  2. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I

    An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.

    Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks)

  3. Number of Participants With AEs and SAEs: Part II

    An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.

    Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part II was 97.0 weeks)

  4. Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I

    Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.

    Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)

  5. Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II

    Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.

    Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)

  6. Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I

    Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

    Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)

  7. Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II

    Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

    Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)

  8. Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I

    Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.

    Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

  9. Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II

    Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.

    Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

  10. Number of Participants With Notable Electrocardiograms (ECG) Values: Part I

    Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

    Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

  11. Number of Participants With Notable ECG Values: Part II

    Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

    Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

  12. Number of Participants With At Least One Dose Interruption: Part I

    In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.

    Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

  13. Number of Participants With At Least One Dose Interruption: Part II

    In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.

    Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

  14. Number of Participants With At Least One Dose Reduction: Part I

    In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.

    Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

  15. Number of Participants With At Least One Dose Reduction: Part II

    In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.

    Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

  16. Actual Dose Intensity: Part I

    Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.

    Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

  17. Actual Dose Intensity: Part II

    Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.

    Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

  18. Progression-Free Survival (PFS): Part I

    PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

    Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part I was 403.7 weeks)

  19. PFS: Part II

    PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

    Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

  20. Duration of Response (DOR): Part I

    DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part I was 403.7 weeks)

  21. DOR: Part II

    DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

  22. Time to Response (TTR): Part I

    TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

    Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part I was 403.7 weeks)

  23. TTR: Part II

    TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

    Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part II was 97.0 weeks)

  24. Disease Control Rate (DCR): Part I

    DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part I was 403.7 weeks)

  25. DCR: Part II

    DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part II was 97.0 weeks)

  26. Overall Survival (OS): Part II

    OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.

    Time frame: From date of start of treatment to date of death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

  27. Summary of Genomic Biomarkers From Tumor Samples: Part I

    Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.

    Time frame: Baseline up to end of treatment (EOT) (maximum treatment exposure for Part I was 403.7 weeks)

  28. Plasma Concentration for Encorafenib (LGX): Part I

    In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.

    Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT

  29. Plasma Concentration for Encorafenib (LGX): Part II

    In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

  30. Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I

    AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.

    Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT

  31. Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II

    AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

  32. Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II

    LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

  33. Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II

    BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; EOT

  34. Plasma Concentration for Capmatinib (INC): Part II

    Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

  35. Plasma Concentration for Buparlisib (BKM): Part II

    Maximum treatment exposure for Part II was of 97.0 weeks.

    Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

  36. Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

    Time frame: C1 D15: 0.5 hour ± 10 (minutes) min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  37. Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  38. Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  39. Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

    Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  40. Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  41. Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  42. Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

    Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

  43. Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

    Time frame: C1 D15: at the end of a dosing interval at steady-state (24 hour ± 2 hour), taken directly before next administration

07

Results

Posted Mar 5, 2024

Participant flow

This study had 2 parts. In Part I, 158 participants were enrolled and treated with encorafenib/ binimetinib (LGX818/MEK162) combination until disease progression (PD) \[as per RECISTv1.1\]. Based on the genetic assessment of a tumor biopsy obtained at PD, participants from Part I entered Part II. In Part II, 58 participants received tailored combination treatment in one of the 4 arms: encorafenib/ binimetinib + buparlisib (BKM120), infigratinib (BGJ398), capmatinib (INC280) or ribociclib (LEE011).

Part I
Participant flow — Part I
MilestonePart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Started75830000
Completed040000
Not completed75790000
Withdrew: Adverse event750000
Withdrew: Death1190000
Withdrew: Progressive disease37460000
Withdrew: New therapy for study indication540000
Withdrew: Termination of participants from the study330000
Withdrew: Physician decision290000
Withdrew: Participant/guardian decision930000
Withdrew: Missing data100000
Part II
Participant flow — Part II
MilestonePart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Started00381136
Completed000000
Not completed00381136
Withdrew: Adverse event001011
Withdrew: Death001021
Withdrew: Progressive disease0035174
Withdrew: New therapy for study indication000010
Withdrew: Physician decision001000
Withdrew: Participant/guardian decision000020

Outcome measures

PrimaryOverall Response Rate (ORR): Part II

ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.

Time frame:
From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR): Part II
Percentage of participantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Overall Response Rate (ORR): Part II2.6 (0.1 to 13.8)0 (NA to NA)0 (0.0 to 24.7)0 (0.0 to 45.9)
SecondaryNumber of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II

DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.

Time frame:
Cycle 1 (21 days following the first dose of the combination treatment with buparlisib and capmatinib; 28 days for the combination with ribociclib and infigratinib)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II1—0—
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I

An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.

Time frame:
Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
AEs7578
SAEs4737
SecondaryNumber of Participants With AEs and SAEs: Part II

An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.

Time frame:
Day 1 up to 30 days after last dose (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs and SAEs: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
AEs371126
SAEs19064
SecondaryNumber of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I

Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.

Time frame:
Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
APTT -CTCAE graded high — Worst post-baseline value Grade 04654
APTT -CTCAE graded high — Worst post-baseline value Grade 114
APTT -CTCAE graded high — Worst post-baseline value Grade 200
APTT -CTCAE graded high — Worst post-baseline value Grade 300
APTT -CTCAE graded high — Worst post-baseline value Grade 400
APTT -CTCAE graded high — Worst post-baseline value Missing2825
Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 02836
Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 189
Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 257
Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 341
Fibrinogen - CTCAE graded low — Worst post-baseline value Grade 400
Fibrinogen - CTCAE graded low — Worst post-baseline value Missing3030
Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 02117
Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 12839
Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 21820
Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 386
Hemoglobin - CTCAE graded low — Worst post-baseline value Grade 400
Hemoglobin - CTCAE graded low — Worst post-baseline value Missing01
Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 07080
Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 142
Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 200
Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 310
Hemoglobin - CTCAE graded high — Worst post-baseline value Grade 400
Hemoglobin - CTCAE graded high — Worst post-baseline value Missing01
PINR -CTCAE graded high — Worst post-baseline value Grade 04434
PINR -CTCAE graded high — Worst post-baseline value Grade 102
PINR -CTCAE graded high — Worst post-baseline value Grade 200
PINR -CTCAE graded high — Worst post-baseline value Grade 300
PINR -CTCAE graded high — Worst post-baseline value Grade 400
PINR -CTCAE graded high — Worst post-baseline value Missing3147
Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 02327
Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 12224
Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 21312
Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 3610
Lymphocytes - CTCAE graded low — Worst post-baseline value Grade 401
Lymphocytes - CTCAE graded low — Worst post-baseline value Missing119
Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 06168
Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 100
Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 226
Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 310
Lymphocytes - CTCAE graded high — Worst post-baseline value Grade 400
Lymphocytes - CTCAE graded high — Worst post-baseline value Missing119
Neutrophils - CTCAE graded low — Worst post-baseline value Grade 05262
Neutrophils - CTCAE graded low — Worst post-baseline value Grade 146
Neutrophils - CTCAE graded low — Worst post-baseline value Grade 254
Neutrophils - CTCAE graded low — Worst post-baseline value Grade 331
Neutrophils - CTCAE graded low — Worst post-baseline value Grade 400
Neutrophils - CTCAE graded low — Worst post-baseline value Missing1110
Platelets - CTCAE graded low — Worst post-baseline value Grade 05971
Platelets - CTCAE graded low — Worst post-baseline value Grade 11411
Platelets - CTCAE graded low — Worst post-baseline value Grade 220
Platelets - CTCAE graded low — Worst post-baseline value Grade 300
Platelets - CTCAE graded low — Worst post-baseline value Grade 400
Platelets - CTCAE graded low — Worst post-baseline value Missing01
Leukocytes - CTCAE graded low — Worst post-baseline value Grade 05261
Leukocytes - CTCAE graded low — Worst post-baseline value Grade 11114
Leukocytes - CTCAE graded low — Worst post-baseline value Grade 233
Leukocytes - CTCAE graded low — Worst post-baseline value Grade 300
Leukocytes - CTCAE graded low — Worst post-baseline value Grade 400
Leukocytes - CTCAE graded low — Worst post-baseline value Missing95
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 06678
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 100
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 200
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 300
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 400
Leukocytes - CTCAE graded high — Worst post-baseline value Missing95
SecondaryNumber of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II

Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.

Time frame:
Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
APTT- CTCAE graded high — Worst post-baseline value Grade 027194
APTT- CTCAE graded high — Worst post-baseline value Grade 10000
APTT- CTCAE graded high — Worst post-baseline value Grade 20000
APTT- CTCAE graded high — Worst post-baseline value Grade 30000
APTT- CTCAE graded high — Worst post-baseline value Grade 40000
APTT- CTCAE graded high — Worst post-baseline value Missing11042
Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 013063
Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 13110
Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 22010
Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 31000
Fibrinogen: CTCAE graded low — Worst post-baseline value Grade 40000
Fibrinogen: CTCAE graded low — Worst post-baseline value Missing19053
Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 04042
Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 115151
Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 214021
Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 34012
Hemoglobin- CTCAE graded low — Worst post-baseline value Grade 40000
Hemoglobin- CTCAE graded low — Worst post-baseline value Missing1010
Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 0371116
Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 10010
Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 20000
Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 30000
Hemoglobin- CTCAE graded high — Worst post-baseline value Grade 40000
Hemoglobin- CTCAE graded high — Worst post-baseline value Missing1010
PINR- CTCAE graded high — Worst post-baseline value Grade 014181
PINR- CTCAE graded high — Worst post-baseline value Grade 10000
PINR- CTCAE graded high — Worst post-baseline value Grade 20000
PINR- CTCAE graded high — Worst post-baseline value Grade 30000
PINR- CTCAE graded high — Worst post-baseline value Grade 40000
PINR- CTCAE graded high — Worst post-baseline value Missing24055
Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 05042
Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 17043
Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 29031
Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 37000
Lymphocytes -CTCAE graded low — Worst post-baseline value Grade 41000
Lymphocytes -CTCAE graded low — Worst post-baseline value Missing9120
Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 0290116
Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 10000
Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 20000
Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 30000
Lymphocytes- CTCAE graded high — Worst post-baseline value Grade 40000
Lymphocytes- CTCAE graded high — Worst post-baseline value Missing9120
Neutrophils- CTCAE graded low — Worst post-baseline value Grade 0100116
Neutrophils- CTCAE graded low — Worst post-baseline value Grade 19000
Neutrophils- CTCAE graded low — Worst post-baseline value Grade 26000
Neutrophils- CTCAE graded low — Worst post-baseline value Grade 31000
Neutrophils- CTCAE graded low — Worst post-baseline value Grade 41000
Neutrophils- CTCAE graded low — Worst post-baseline value Missing11120
Platelets- CTCAE graded low — Worst post-baseline value Grade 0331116
Platelets- CTCAE graded low — Worst post-baseline value Grade 14010
Platelets- CTCAE graded low — Worst post-baseline value Grade 20000
Platelets- CTCAE graded low — Worst post-baseline value Grade 30000
Platelets- CTCAE graded low — Worst post-baseline value Grade 40000
Platelets- CTCAE graded low — Worst post-baseline value Missing1010
Leukocytes- CTCAE graded low — Worst post-baseline value Grade 080116
Leukocytes- CTCAE graded low — Worst post-baseline value Grade 18000
Leukocytes- CTCAE graded low — Worst post-baseline value Grade 212000
Leukocytes- CTCAE graded low — Worst post-baseline value Grade 33000
Leukocytes- CTCAE graded low — Worst post-baseline value Grade 40000
Leukocytes- CTCAE graded low — Worst post-baseline value Missing7120
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 0310116
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 10000
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 20000
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 30000
Leukocytes - CTCAE graded high — Worst post-baseline value Grade 40000
Leukocytes - CTCAE graded high — Worst post-baseline value Missing7120
SecondaryNumber of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I

Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

Time frame:
Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Albumin - CTCAE graded low — Worst post-baseline value Grade 03240
Albumin - CTCAE graded low — Worst post-baseline value Grade 13529
Albumin - CTCAE graded low — Worst post-baseline value Grade 2812
Albumin - CTCAE graded low — Worst post-baseline value Grade 301
Albumin - CTCAE graded low — Worst post-baseline value Grade 400
Albumin - CTCAE graded low — Worst post-baseline value Missing01
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 03943
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 12831
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 255
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 333
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 400
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Missing01
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 03851
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 12728
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 252
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 350
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 400
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Missing02
Amylase - CTCAE graded high — Worst post-baseline value Grade 05352
Amylase - CTCAE graded high — Worst post-baseline value Grade 1146
Amylase - CTCAE graded high — Worst post-baseline value Grade 252
Amylase - CTCAE graded high — Worst post-baseline value Grade 322
Amylase - CTCAE graded high — Worst post-baseline value Grade 401
Amylase - CTCAE graded high — Worst post-baseline value Missing120
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 03850
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 13029
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 242
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 331
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 400
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Missing01
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 07381
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 110
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 210
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 301
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 400
Bilirubin - CTCAE graded high — Worst post-baseline value Missing01
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 02256
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 13015
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 2188
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 342
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 411
Creatine Kinase - CTCAE graded high — Worst post-baseline value Missing01
Creatinine - CTCAE graded high — Worst post-baseline value Grade 024
Creatinine - CTCAE graded high — Worst post-baseline value Grade 15756
Creatinine - CTCAE graded high — Worst post-baseline value Grade 21422
Creatinine - CTCAE graded high — Worst post-baseline value Grade 320
Creatinine - CTCAE graded high — Worst post-baseline value Grade 400
Creatinine - CTCAE graded high — Worst post-baseline value Missing01
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 02033
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 11918
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 21413
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 32015
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 423
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Missing01
Glucose - CTCAE graded low — Worst post-baseline value Grade 05567
Glucose - CTCAE graded low — Worst post-baseline value Grade 1157
Glucose - CTCAE graded low — Worst post-baseline value Grade 211
Glucose - CTCAE graded low — Worst post-baseline value Grade 300
Glucose - CTCAE graded low — Worst post-baseline value Grade 400
Glucose - CTCAE graded low — Worst post-baseline value Missing48
Glucose - CTCAE graded high — Worst post-baseline value Grade 05660
Glucose - CTCAE graded high — Worst post-baseline value Grade 1410
Glucose - CTCAE graded high — Worst post-baseline value Grade 230
Glucose - CTCAE graded high — Worst post-baseline value Grade 375
Glucose - CTCAE graded high — Worst post-baseline value Grade 410
Glucose - CTCAE graded high — Worst post-baseline value Missing48
Potassium - CTCAE graded low — Worst post-baseline value Grade 06574
Potassium - CTCAE graded low — Worst post-baseline value Grade 175
Potassium - CTCAE graded low — Worst post-baseline value Grade 200
Potassium - CTCAE graded low — Worst post-baseline value Grade 333
Potassium - CTCAE graded low — Worst post-baseline value Grade 400
Potassium - CTCAE graded low — Worst post-baseline value Missing01
Potassium - CTCAE graded high — Worst post-baseline value Grade 05466
Potassium - CTCAE graded high — Worst post-baseline value Grade 11815
Potassium - CTCAE graded high — Worst post-baseline value Grade 220
Potassium - CTCAE graded high — Worst post-baseline value Grade 310
Potassium - CTCAE graded high — Worst post-baseline value Grade 401
Potassium - CTCAE graded high — Worst post-baseline value Missing01
Magnesium - CTCAE graded low — Worst post-baseline value Grade 06668
Magnesium - CTCAE graded low — Worst post-baseline value Grade 1814
Magnesium - CTCAE graded low — Worst post-baseline value Grade 200
Magnesium - CTCAE graded low — Worst post-baseline value Grade 310
Magnesium - CTCAE graded low — Worst post-baseline value Grade 400
Magnesium - CTCAE graded low — Worst post-baseline value Missing01
Magnesium - CTCAE graded high — Worst post-baseline value Grade 07479
Magnesium - CTCAE graded high — Worst post-baseline value Grade 113
Magnesium - CTCAE graded high — Worst post-baseline value Grade 200
Magnesium - CTCAE graded high — Worst post-baseline value Grade 300
Magnesium - CTCAE graded high — Worst post-baseline value Grade 400
Magnesium - CTCAE graded high — Worst post-baseline value Missing01
Phosphate - CTCAE graded low — Worst post-baseline value Grade 04062
Phosphate - CTCAE graded low — Worst post-baseline value Grade 133
Phosphate - CTCAE graded low — Worst post-baseline value Grade 22412
Phosphate - CTCAE graded low — Worst post-baseline value Grade 384
Phosphate - CTCAE graded low — Worst post-baseline value Grade 401
Phosphate - CTCAE graded low — Worst post-baseline value Missing01
Sodium - CTCAE graded low — Worst post-baseline value Grade 05453
Sodium - CTCAE graded low — Worst post-baseline value Grade 12124
Sodium - CTCAE graded low — Worst post-baseline value Grade 200
Sodium - CTCAE graded low — Worst post-baseline value Grade 305
Sodium - CTCAE graded low — Worst post-baseline value Grade 400
Sodium - CTCAE graded low — Worst post-baseline value Missing01
Sodium - CTCAE graded high — Worst post-baseline value Grade 06675
Sodium - CTCAE graded high — Worst post-baseline value Grade 196
Sodium - CTCAE graded high — Worst post-baseline value Grade 201
Sodium - CTCAE graded high — Worst post-baseline value Grade 300
Sodium - CTCAE graded high — Worst post-baseline value Grade 400
Sodium - CTCAE graded high — Worst post-baseline value Missing01
Urate - CTCAE graded high — Worst post-baseline value Grade 07582
Urate - CTCAE graded high — Worst post-baseline value Grade 100
Urate - CTCAE graded high — Worst post-baseline value Grade 200
Urate - CTCAE graded high — Worst post-baseline value Grade 300
Urate - CTCAE graded high — Worst post-baseline value Grade 400
Urate - CTCAE graded high — Worst post-baseline value Missing01
SecondaryNumber of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II

Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

Time frame:
Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Albumin- CTCAE graded low — Worst post-baseline value Grade 016113
Albumin- CTCAE graded low — Worst post-baseline value Grade 113060
Albumin- CTCAE graded low — Worst post-baseline value Grade 27031
Albumin- CTCAE graded low — Worst post-baseline value Grade 31021
Albumin- CTCAE graded low — Worst post-baseline value Grade 40000
Albumin- CTCAE graded low — Worst post-baseline value Missing1011
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 022171
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 110034
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 23021
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 32000
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Grade 40000
Alkaline Phosphatase - CTCAE graded high — Worst post-baseline value Missing1010
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 027194
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 16021
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 22000
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 31010
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 41001
Alanine Aminotransferase - CTCAE graded high — Worst post-baseline value Missing1010
Amylase - CTCAE graded high — Worst post-baseline value Grade 027191
Amylase - CTCAE graded high — Worst post-baseline value Grade 11020
Amylase - CTCAE graded high — Worst post-baseline value Grade 20001
Amylase - CTCAE graded high — Worst post-baseline value Grade 30000
Amylase - CTCAE graded high — Worst post-baseline value Grade 42000
Amylase - CTCAE graded high — Worst post-baseline value Missing8024
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 027183
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 16042
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 23000
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 31001
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Grade 40000
Aspartate Aminotransferase - CTCAE graded high — Worst post-baseline value Missing1010
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 0371126
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 10000
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 20000
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 30000
Bilirubin - CTCAE graded high — Worst post-baseline value Grade 40000
Bilirubin - CTCAE graded high — Worst post-baseline value Missing1010
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 020063
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 114142
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 23000
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 30020
Creatine Kinase - CTCAE graded high — Worst post-baseline value Grade 40000
Creatine Kinase - CTCAE graded high — Worst post-baseline value Missing1011
Creatinine - CTCAE graded high — Worst post-baseline value Grade 01001
Creatinine - CTCAE graded high — Worst post-baseline value Grade 125143
Creatinine - CTCAE graded high — Worst post-baseline value Grade 211081
Creatinine - CTCAE graded high — Worst post-baseline value Grade 30000
Creatinine - CTCAE graded high — Worst post-baseline value Grade 40000
Creatinine - CTCAE graded high — Worst post-baseline value Missing1011
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 020150
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 19021
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 21022
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 37033
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Grade 40000
Gamma Glutamyl Transferase - CTCAE graded high — Worst post-baseline value Missing1010
Glucose - CTCAE graded low — Worst post-baseline value Grade 0240115
Glucose - CTCAE graded low — Worst post-baseline value Grade 16110
Glucose - CTCAE graded low — Worst post-baseline value Grade 20000
Glucose - CTCAE graded low — Worst post-baseline value Grade 30000
Glucose - CTCAE graded low — Worst post-baseline value Grade 40000
Glucose - CTCAE graded low — Worst post-baseline value Missing8011
Glucose - CTCAE graded high — Worst post-baseline value Grade 0261104
Glucose - CTCAE graded high — Worst post-baseline value Grade 12011
Glucose - CTCAE graded high — Worst post-baseline value Grade 20000
Glucose - CTCAE graded high — Worst post-baseline value Grade 31010
Glucose - CTCAE graded high — Worst post-baseline value Grade 41000
Glucose - CTCAE graded high — Worst post-baseline value Missing8011
Potassium - CTCAE graded low — Worst post-baseline value Grade 0341115
Potassium - CTCAE graded low — Worst post-baseline value Grade 13010
Potassium - CTCAE graded low — Worst post-baseline value Grade 20000
Potassium - CTCAE graded low — Worst post-baseline value Grade 30000
Potassium - CTCAE graded low — Worst post-baseline value Grade 40000
Potassium - CTCAE graded low — Worst post-baseline value Missing1011
Potassium - CTCAE graded high — Worst post-baseline value Grade 032193
Potassium - CTCAE graded high — Worst post-baseline value Grade 14032
Potassium - CTCAE graded high — Worst post-baseline value Grade 21000
Potassium - CTCAE graded high — Worst post-baseline value Grade 30000
Potassium - CTCAE graded high — Worst post-baseline value Grade 40000
Potassium - CTCAE graded high — Worst post-baseline value Missing1011
Magnesium - CTCAE graded low — Worst post-baseline value Grade 0351104
Magnesium - CTCAE graded low — Worst post-baseline value Grade 12021
Magnesium - CTCAE graded low — Worst post-baseline value Grade 20000
Magnesium - CTCAE graded low — Worst post-baseline value Grade 30000
Magnesium - CTCAE graded low — Worst post-baseline value Grade 40000
Magnesium - CTCAE graded low — Worst post-baseline value Missing1011
Magnesium - CTCAE graded high — Worst post-baseline value Grade 0361125
Magnesium - CTCAE graded high — Worst post-baseline value Grade 11000
Magnesium - CTCAE graded high — Worst post-baseline value Grade 20000
Magnesium - CTCAE graded high — Worst post-baseline value Grade 30000
Magnesium - CTCAE graded high — Worst post-baseline value Grade 40000
Magnesium - CTCAE graded high — Worst post-baseline value Missing1011
Phosphate - CTCAE graded low — Worst post-baseline value Grade 025174
Phosphate - CTCAE graded low — Worst post-baseline value Grade 12011
Phosphate - CTCAE graded low — Worst post-baseline value Grade 27030
Phosphate - CTCAE graded low — Worst post-baseline value Grade 31010
Phosphate - CTCAE graded low — Worst post-baseline value Grade 42000
Phosphate - CTCAE graded low — Worst post-baseline value Missing1011
Sodium -CTCAE graded low — Worst post-baseline value Grade 0281103
Sodium -CTCAE graded low — Worst post-baseline value Grade 17022
Sodium -CTCAE graded low — Worst post-baseline value Grade 20000
Sodium -CTCAE graded low — Worst post-baseline value Grade 32000
Sodium -CTCAE graded low — Worst post-baseline value Grade 40000
Sodium -CTCAE graded low — Worst post-baseline value Missing1011
Sodium - CTCAE graded high — Worst post-baseline value Grade 0351124
Sodium - CTCAE graded high — Worst post-baseline value Grade 12001
Sodium - CTCAE graded high — Worst post-baseline value Grade 20000
Sodium - CTCAE graded high — Worst post-baseline value Grade 30000
Sodium - CTCAE graded high — Worst post-baseline value Grade 40000
Sodium - CTCAE graded high — Worst post-baseline value Missing1011
Urate - CTCAE graded high — Worst post-baseline value Grade 0371125
Urate - CTCAE graded high — Worst post-baseline value Grade 10000
Urate - CTCAE graded high — Worst post-baseline value Grade 20000
Urate - CTCAE graded high — Worst post-baseline value Grade 30000
Urate - CTCAE graded high — Worst post-baseline value Grade 40000
Urate - CTCAE graded high — Worst post-baseline value Missing1011
SecondaryNumber of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I

Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.

Time frame:
During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Sitting Pulse Rate: High28
Sitting Pulse Rate: Low54
Sitting Systolic BP: High185
Sitting Systolic BP: Low32
Sitting Diastolic BP: High114
Sitting Diastolic BP: Low53
Weight: High02
Weight: Low00
Body temperature: High1414
Body temperature: Low4436
SecondaryNumber of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II

Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.

Time frame:
During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Sitting Pulse Rate: High2001
Sitting Pulse Rate: Low1000
Sitting Systolic BP: High2040
Sitting Systolic BP: Low0000
Sitting Diastolic BP: High2010
Sitting Diastolic BP: Low1000
Weight: High0000
Weight: Low1000
Body temperature: High3011
Body temperature: Low14163
SecondaryNumber of Participants With Notable Electrocardiograms (ECG) Values: Part I

Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

Time frame:
During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Notable Electrocardiograms (ECG) Values: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
HR: Increase from baseline >25% & to a value >100 bpm105
HR: Decrease from baseline >25% & to a value <60 bpm3723
PR: Increase from baseline >25% & to a value >200 ms51
QRS: Increase from baseline >25% & to a value >110 ms30
QT: Increase from baseline >30 ms6148
QT: Increase from baseline >60 ms2915
QT: New Interval >450 ms244
QT: New Interval >480 ms53
QT: New Interval >500 ms30
QTcF: Increase from baseline >30 ms4631
QTcF: Increase from baseline >60 ms42
QTcF: New Interval >450 ms2815
QTcF: New Interval >480 ms40
QTcF: New Interval >500 ms10
SecondaryNumber of Participants With Notable ECG Values: Part II

Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

Time frame:
During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Notable ECG Values: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
HR: Increase from baseline >25% & to a value >100 bpm3021
HR: Decrease from baseline >25% & to a value <60 bpm14070
PR: Increase from baseline >25% & to a value >200 ms1020
QRS: Increase from baseline >25% & to a value >110 ms0000
QT: Increase from baseline >30 ms24090
QT: Increase from baseline >60 ms2000
QT: New Interval >450 ms3—30
QT: New Interval >480 ms1000
QT: New Interval >500 ms0000
QTcF: Increase from baseline >30 ms11021
QTcF: Increase from baseline >60 ms0000
QTcF: New Interval >450 ms14030
QTcF: New Interval >480 ms0000
QTcF: New Interval >500 ms0000
SecondaryNumber of Participants With At Least One Dose Interruption: Part I

In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.

Time frame:
During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With At Least One Dose Interruption: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Encorafenib4640
Binimetinib4441
SecondaryNumber of Participants With At Least One Dose Interruption: Part II

In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.

Time frame:
During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With At Least One Dose Interruption: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Encorafenib14042
Binimetinib13053
Ribociclib11———
Infigratinib—0——
Capmatinib——5—
Buparlisib———2
SecondaryNumber of Participants With At Least One Dose Reduction: Part I

In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.

Time frame:
During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With At Least One Dose Reduction: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Encorafenib914
Binimetinib3228
SecondaryNumber of Participants With At Least One Dose Reduction: Part II

In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.

Time frame:
During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Count of participants · Participants
Number of Participants With At Least One Dose Reduction: Part II
ParticipantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Encorafenib1001
Binimetinib11053
Ribociclib1———
Infigratinib—0——
Capmatinib——7—
Buparlisib———1
SecondaryActual Dose Intensity: Part I

Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.

Time frame:
During study treatment (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Mean · Milligram per day
Actual Dose Intensity: Part I
Milligram per dayPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Encorafenib425.311 ± 53.5392408.711 ± 65.5297
Binimetinib81.920 ± 13.099482.083 ± 10.9117
SecondaryActual Dose Intensity: Part II

Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.

Time frame:
During study treatment (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Mean · Milligram per day
Actual Dose Intensity: Part II
Milligram per dayPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Encorafenib197.856 ± 42.6637450.000 ± NA195.945 ± 8.4015405.014 ± 102.5218
Binimetinib79.749 ± 14.726790.000 ± NA87.373 ± 3.659378.791 ± 20.1538
Ribociclib486.628 ± 79.4485———
Infigratinib—60.227 ± NA——
Capmatinib——579.519 ± 259.1157—
Buparlisib———72.206 ± 15.7019
SecondaryProgression-Free Survival (PFS): Part I

PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

Time frame:
From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Median · Months
Progression-Free Survival (PFS): Part I
MonthsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Progression-Free Survival (PFS): Part I11.1 (8.1 to 15.0)3.3 (2.1 to 4.7)
SecondaryPFS: Part II

PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

Time frame:
From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Median · Months
PFS: Part II
MonthsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
PFS: Part II2.1 (1.7 to 2.1)2.1 (NA to NA)2.1 (1.0 to 3.7)1.4 (0.4 to NA)
SecondaryDuration of Response (DOR): Part I

DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Median · Months
Duration of Response (DOR): Part I
MonthsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Duration of Response (DOR): Part I10.9 (8.1 to 14.1)5.6 (3.9 to 13.0)
SecondaryDOR: Part II

DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Median · Months
DOR: Part II
MonthsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
DOR: Part II2.1 (NA to NA)———
SecondaryTime to Response (TTR): Part I

TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

Time frame:
From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Median · Months
Time to Response (TTR): Part I
MonthsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Time to Response (TTR): Part I1.4 (1.38 to 1.41)0.72 (0.72 to 0.82)
SecondaryTTR: Part II

TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

Time frame:
From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Median · Months
TTR: Part II
MonthsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
TTR: Part II4.1 (NA to NA)———
SecondaryDisease Control Rate (DCR): Part I

DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR): Part I
Percentage of participantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Disease Control Rate (DCR): Part I92.0 (83.4 to 97.0)42.2 (31.4 to 53.5)
SecondaryDCR: Part II

DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Number · Percentage of participants
DCR: Part II
Percentage of participantsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
DCR: Part II26.3 (13.4 to 43.1)0 (NA to NA)15.4 (1.9 to 45.4)16.7 (0.4 to 64.1)
SecondaryOverall Survival (OS): Part II

OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.

Time frame:
From date of start of treatment to date of death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)
Reported as:
Median · Months
Overall Survival (OS): Part II
MonthsPart II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Overall Survival (OS): Part II10.4 (6.0 to 16.7)20.8 (NA to NA)5.6 (1.7 to NA)2.5 (0.4 to NA)
SecondarySummary of Genomic Biomarkers From Tumor Samples: Part I

Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.

Time frame:
Baseline up to end of treatment (EOT) (maximum treatment exposure for Part I was 403.7 weeks)
Reported as:
Count of participants · Participants
Summary of Genomic Biomarkers From Tumor Samples: Part I
ParticipantsPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
BRAF: CNV/CNR at Baseline49
BRAF: CNV/CNR at EOT23
BRAF: Rearrangement/Genomic Position at Baseline chr7:140482508-14048269201
BRAF: Rearrangement/Genomic Position at Baseline chr7:140487121-14048728501
BRAF: Rearrangement/Genomic Position at Baseline chr7:140487916-14048816701
BRAF: Rearrangement/Genomic Position at Baseline chr7:140488878-14048905501
BRAF: Rearrangement/Genomic Position at Baseline cchr7:140489413-14048957601
BRAF: Rearrangement/Genomic Position at Baseline chr7:140490446-14049065601
BRAF: Rearrangement/Genomic Position at Baseline chr7:140491528-14049187801
BRAF: Rearrangement/Genomic Position at Baseline chr7:140491580-14049187801
BRAF: Rearrangement/Genomic Position at Baseline chr7:140492969-14049330101
BRAF: Rearrangement/Genomic Position at EOT chr7:140481691-14048215010
BRAF: Rearrangement/Genomic Position at EOT chr7:140482057-14048246701
BRAF: Rearrangement/Genomic Position at EOT chr7:140482081-14048248210
BRAF: Rearrangement/Genomic Position at EOT chr7:140482088-14048229601
BRAF: Rearrangement/Genomic Position at EOT chr7:140482167-14048238210
BRAF: Rearrangement/Genomic Position at EOT chr7:140482495-14048273101
BRAF: Rearrangement/Genomic Position at EOT chr7:140482644-14048286701
BRAF: Rearrangement/Genomic Position at EOT chr7:140483058-14048325710
BRAF: Rearrangement/Genomic Position at EOT chr7:140486136-14048640810
BRAF: Rearrangement/Genomic Position at EOT chr7:140486274-14048656101
BRAF: Rearrangement/Genomic Position at EOT chr7:140489019-14048957501
BRAF: Rearrangement/Genomic Position at EOT chr7:140489219-14048943110
BRAF: Rearrangement/Genomic Position at EOT chr7:140489830-14049000201
BRAF: Rearrangement/Genomic Position at EOT chr7:140491411-14049187901
BRAF: Rearrangement/Genomic Position at EOT chr7:140492091-14049224010
BRAF: Rearrangement/Genomic Position at EOT chr7:140492379-14049270801
BRAF: Rearrangement/Genomic Position at EOT chr7:140492714-14049299701
BRAF: Rearrangement/Genomic Position at EOT chr7:140493601-14049395101
BRAF: Rearrangement/Genomic Position at EOT chr7:140493858-14049423210
BRAF: Short variant/amino acid change at Baseline V600E4653
BRAF: Short variant/amino acid change at Baseline V600G10
BRAF: Short variant/amino acid change at Baseline V600K47
BRAF: Short variant/amino acid change at Baseline V600R10
BRAF: Short variant/amino acid change at EOT V600E1819
BRAF: Short variant/amino acid change at EOT V600K04
BRAF: Short variant/amino acid change at EOT V600R10
CCND1: CNV/CNR at Baseline10
CDK4: CNV/CNR at Baseline32
EGFR: CNV/CNR at Baseline13
EGFR: CNV/CNR at EOT11
FGFR1: CNV/CNR at Baseline10
FGFR1: CNV/CNR at EOT10
FGFR4: CNV/CNR at Baseline10
KRAS: CNV/CNR at Baseline20
MET: CNV/CNR at Baseline46
MET: CNV/CNR at EOT35
MET: Rearrangement/Genomic Position at EOT chr7:116321020-11632126010
NRAS: CNV/CNR at Baseline01
PIK3CA: CNV/CNR at Baseline10
PTEN: CNV/CNR at Baseline413
PTEN: CNV/CNR at EOT510
PTEN: Rearrangement/Genomic Position at EOT chr10:89720538-8972077601
SecondaryPlasma Concentration for Encorafenib (LGX): Part I

In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.

Time frame:
C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Encorafenib (LGX): Part I
Nanogram per milliliterPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
C1 D1, 1.5 hr4820 ± 114.24480 ± 124.4
C1 D15, Pre-dose10.0 ± 81.613.8 ± 104.4
C1 D15, 1.5 hr2470 ± 116.72910 ± 91.6
C2 D8, Pre-dose9.96 ± 81.714.7 ± 117.5
C2 D21, Pre-dose9.04 ± 84.215.6 ± 156.3
C3 D15, Pre-dose8.43 ± 82.311.2 ± 114.3
C4 D15, Pre-dose9.21 ± 100.312.3 ± 108.9
C5 D15, Pre-dose8.84 ± 59.411.9 ± 72.7
EOT19.6 ± 399.934.5 ± 890.3
SecondaryPlasma Concentration for Encorafenib (LGX): Part II

In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Encorafenib (LGX): Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg
C1 D1: 1.5 hrs—3430 ± 17.61860 ± NA1130 ± 3.83750 ± NA1770 ± 62.9878 ± NA2030 ± NA847 ± 28.1—1600 ± 85.6
C1 D1: 4 hrs——————238 ± NA297 ± NA626 ± 65.7—596 ± 51.1
C1 D8: Pre-dose8.97 ± 89.021.3 ± 150.612.4 ± NA10.3 ± 54.46.21 ± NA11.7 ± 56.412.5 ± NA15.2 ± NA9.39 ± 15.97.15 ± NA16.2 ± 116.1
C1 D15: Pre-dose11.2 ± 106.318.6 ± 159.47.74 ± NA9.95 ± 40.17.95 ± NA13.5 ± 35.09.28 ± NA10.3 ± NA7.75 ± 37.3—20.9 ± 188.5
C1 D15: 0.5 hr437 ± 228.2625 ± 19.51690 ± NA262 ± 345.5139 ± NA127 ± 216.18.55 ± NA601 ± NA473 ± 1248.5—175 ± 252.7
C1 D15: 1.5 hrs3050 ± 59.62150 ± 54.62100 ± NA1550 ± 62.42890 ± NA2500 ± 27.9366 ± NA1960 ± NA1450 ± 3.9—1850 ± 69.7
C1 D15: 2.5 hrs1420 ± 39.61320 ± 30.01020 ± NA808 ± 55.0—1550 ± 34.4622 ± NA981 ± NA686 ± NA—1510 ± 48.2
C1 D15: 4 hrs649 ± 37.5770 ± 6.2397 ± NA453 ± 24.31160 ± NA667 ± 20.4389 ± NA—478 ± 39.6—1020 ± 34.3
C1 D15: 6 hrs246 ± 94.6433 ± 45.0211 ± NA165 ± 68.8266 ± NA317 ± 26.8209 ± NA199 ± NA203 ± 11.1—567 ± 51.5
C1 D15: 8 hrs180 ± 94.5276 ± 103.8—115 ± 55.4257 ± NA217 ± 34.5142 ± NA132 ± NA109 ± 2.6—412 ± 62.3
C1 D16: 24 hrs11.3 ± 45.325.1 ± 2066.86.76 ± NA8.10 ± 43.15.20 ± NA15.0 ± 20.910.7 ± NA7.85 ± NA10.8 ± 106.1—22.8 ± 199.0
C1 D21: Pre-dose——10.4 ± NA———13.6 ± NA13.9 ± NA12.4 ± 60.420.3 ± NA17.5 ± 106.4
C2 D1: Pre-dose13.5 ± 193.032.6 ± 202.912.7 ± NA19.9 ± 210.52.91 ± NA14.0 ± 30.38.50 ± NA82.5 ± NA8.19 ± 42.219.2 ± NA11.9 ± 100.9
C2 D15: Pre-dose41.3 ± NA15.6 ± NA13.9 ± NA9.68 ± 36.5—8.49 ± 70.511.1 ± NA16.5 ± NA12.3 ± 24.38.95 ± NA21.3 ± 115.3
C3 D1: Pre-dose13.9 ± NA—20.5 ± NA23.2 ± 33.1—10.1 ± 72.1—NA ± NA——9.34 ± 125.7
C4 D1: Pre-dose30.2 ± NA————12.5 ± 11.45.95 ± NA7.28 ± NA——13.1 ± 21.8
C5 D1: Pre-dose749 ± NA—————10.7 ± NA9.84 ± NA——9.15 ± 44.0
EOT1.77 ± NANA ± NA14.3 ± NANA ± NANA ± NA13.9 ± 66.68.24 ± NA6.81 ± NA24.5 ± 259.8NA ± NA16.6 ± 265.0
SecondaryPlasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I

AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.

Time frame:
C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I
Nanogram per milliliterPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)
Binimetinib: C1 D1, 1.5 hr551 ± 88.8482 ± 73.4
Binimetinib: C1 D15, Pre-dose40.3 ± 63.543.3 ± 72.9
Binimetinib: C1 D15, 1.5 hr461 ± 70.2451 ± 50.2
Binimetinib: C2 D8, Pre-dose39.9 ± 58.844.8 ± 73.0
Binimetinib: C2 D21, Pre-dose38.9 ± 54.953.1 ± 78.2
Binimetinib: C3 D15, Pre-dose41.9 ± 60.438.7 ± 94.6
Binimetinib: C4 D15, Pre-dose36.2 ± 68.638.8 ± 57.4
Binimetinib: C5 D15, Pre-dose41.3 ± 55.739.2 ± 76.1
Binimetinib: EOT33.2 ± 179.452.8 ± 180.4
AR00426032: C1 D1, 1.5 hr57.6 ± 93.547.5 ± 101.6
AR00426032: C1 D15, Pre-dose4.13 ± 70.84.50 ± 64.0
AR00426032: C1 D15, 1.5 hr30.6 ± 110.931.9 ± 84.0
AR00426032: C2 D8, Pre-dose3.63 ± 60.24.17 ± 88.1
AR00426032: C2 D21, Pre-dose4.11 ± 61.04.39 ± 80.2
AR00426032: C3 D15, Pre-dose3.71 ± 59.53.90 ± 60.6
AR00426032: C4 D15, Pre-dose3.48 ± 65.83.81 ± 56.9
AR00426032: C5 D15, Pre-dose3.77 ± 66.93.36 ± 67.3
AR00426032: EOT4.09 ± 90.85.88 ± 118.0
SecondaryPlasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II

AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg
Binimetinib, C1 D1: 1.5 hrs—410 ± 48.8416 ± NA313 ± 25.61100 ± NA508 ± 130.2396 ± NA649 ± NA273 ± 24.6—446 ± 59.8522 ± NA1230 ± NA
Binimetinib, C1 D1: 4 hrs——————152 ± NA106 ± NA129 ± 25.8—215 ± 44.599.5 ± NA—
Binimetinib, C1 D8: Pre-dose41.6 ± 21.751.1 ± 9.746.0 ± NA74.6 ± 34.527.2 ± NA67.4 ± 63.163.0 ± NA31.5 ± NA25.1 ± 1.727.2 ± NA51.0 ± 67.837.3 ± NA—
Binimetinib, C1 D15: Pre-dose32.0 ± 17.139.1 ± 57.433.9 ± NA85.6 ± 53.747.3 ± NA50.9 ± 34.454.3 ± NA28.3 ± NA21.1 ± 23.7—48.2 ± 70.036.2 ± NA—
Binimetinib, C1 D15: 0.5 hr150 ± 36.1143 ± 496.2315 ± NA430 ± 26.8401 ± NA180 ± 91.5229 ± NA389 ± NA161 ± 54.7—158 ± 90.1——
Binimetinib, C1 D15: 1.5 hrs386 ± 41.1187 ± 351.0413 ± NA489 ± 27.1797 ± NA734 ± 45.6261 ± NA520 ± NA313 ± 15.9—437 ± 46.5——
Binimetinib, C1 D15: 2.5 hrs250 ± 17.1143 ± 172.4235 ± NA295 ± 29.7—491 ± 38.0207 ± NA331 ± NA154 ± NA—380 ± 31.2178 ± NA—
Binimetinib, C1 D15: 4 hrs147 ± 21.4125 ± 62.198.0 ± NA166 ± 48.9264 ± NA266 ± 32.5130 ± NA—98.0 ± 60.0—241 ± 28.6——
Binimetinib, C1 D15: 6 hrs79.0 ± 36.197.3 ± 32.855.8 ± NA106 ± 53.3112 ± NA141 ± 15.1167 ± NA77.4 ± NA53.3 ± 36.2—134 ± 46.5——
Binimetinib, C1 D15: 8 hrs74.9 ± 34.759.7 ± 12.6—107 ± 40.9132 ± NA102 ± 12.4116 ± NA65.5 ± NA42.2 ± 39.2—109 ± 54.8——
Binimetinib, C1 D16: 24 hrs44.1 ± 19.130.2 ± 59.242.1 ± NA63.2 ± 64.017.6 ± NA55.9 ± 54.078.3 ± NA29.8 ± NA23.1 ± 5.2—55.2 ± 66.040.5 ± NA—
Binimetinib, C1 D21: Pre-dose——34.0 ± NA———40.4 ± NA38.8 ± NA13.6 ± 80.719.6 ± NA63.2 ± 51.035.3 ± NA8.91 ± NA
Binimetinib, C2 D1: Pre-dose38.8 ± 62.542.7 ± 27.840.5 ± NA118 ± 120.124.6 ± NA54.2 ± 32.458.3 ± NA174 ± NA23.3 ± 20.258.3 ± NA46.0 ± 71.222.4 ± NA54.1 ± NA
Binimetinib, C2 D15: Pre-dose63.7 ± NA73.0 ± NA63.9 ± NA40.9 ± 50.818.9 ± NA49.8 ± 21.263.1 ± NA19.4 ± NA15.2 ± 18.214.1 ± NA58.4 ± 68.327.3 ± NA34.9 ± NA
Binimetinib, C3 D1: Pre-dose50.0 ± NA—47.2 ± NA37.8 ± 189.6—41.9 ± 49.053.4 ± NA4.82 ± NA——45.0 ± 91.842.0 ± NA—
Binimetinib, C4 D1: Pre-dose46.1 ± NA————53.8 ± 10.663.6 ± NA40.9 ± NA——77.5 ± 32.1——
Binimetinib, C5 D1: Pre-dose60.0 ± NA—————42.3 ± NA28.5 ± NA——73.8 ± 25.7——
Binimetinib, EOTNA ± NANA ± NA36.3NA ± NANA ± NA52.1 ± 18.341.0 ± NA32.3 ± NA13.8 ± 205.5NA ± NA29.0 ± 179.7——
AR00426032, C1 D1: 1.5 hrs—22.4 ± 200.612.9 ± NA11.4 ± 85.7—35.9 ± 274.1—22.1 ± NA8.05 ± 68.9—19.4 ± 99.316.3 ± NA64.6 ± NA
AR00426032, C1 D1: 4 hrs——————9.40 ± NA4.09 ± NA6.71 ± 145.3—12.3 ± 75.34.61 ± NA—
AR00426032, C1 D8: Pre-dose3.98 ± 31.92.95 ± 165.31.21 ± NA7.10 ± 122.1—6.34 ± 54.56.15 ± NA1.10 ± NA1.73 ± 48.72.09 ± NA5.50 ± 62.62.14 ± NA—
AR00426032, C1 D15: Pre-dose3.14 ± 74.53.80 ± 111.91.21 ± NA11.5 ± 39.54.36 ± NA5.45 ± 42.24.16 ± NANA ± NA3.81 ± NA—4.19 ± 79.21.09 ± NA—
AR00426032, C1 D15: 0.5 hr6.66 ± 43.27.43 ± 455.18.21 ± NA13.1 ± 97.811.4 ± NA9.80 ± 75.77.31 ± NA4.35 ± NA6.16 ± 490.6—7.81 ± 119.0——
AR00426032, C1 D15: 1.5 hrs24.9 ± 92.213.2 ± 1550.115.8 ± NA27.9 ± 85.6—41.1 ± 25.712.9 ± NA12.6 ± NA16.1 ± 151.9—18.3 ± 135.9——
AR00426032, C1 D15: 2.5 hrs18.5 ± 77.011.3 ± 447.27.75 ± NA18.5 ± 88.4—34.3 ± 51.39.71 ± NA8.51 ± NA16.2 ± NA—18.5 ± 81.24.73 ± NA—
AR00426032, C1 D15: 4 hrs11.8 ± 40.39.98 ± 142.43.15 ± NA9.46 ± 142.722.6 ± NA19.3 ± 76.96.76 ± NA—5.21 ± 81.9—12.2 ± 78.7——
AR00426032, C1 D15: 6 hrs6.86 ± 61.87.66 ± 117.71.82 ± NA6.90 ± 142.38.89 ± NA9.66 ± 71.55.82 ± NA2.52 ± NA3.07 ± 95.0—7.41 ± 80.2——
AR00426032b, C1 D15: 8 hrs5.94 ± 76.75.24 ± 70.7—6.49 ± 124.98.06 ± NA8.87 ± 76.55.12 ± NA1.95 ± NA2.67 ± 72.9—6.73 ± 75.0——
AR00426032, C1 D16: 24 hrs3.99 ± 61.82.92 ± 159.31.27 ± NA7.79 ± 87.51.44 ± NA4.75 ± 25.46.53 ± NA1.08 ± NA3.19 ± NA—4.70 ± 80.21.56 ± NA—
AR00426032, C1 D21: Pre-dose——NA ± NA———3.66 ± NA1.47 ± NA3.18 ± NA1.13 ± NA6.64 ± 56.11.65 ± NA3.11 ± NA
AR00426032, C2 D1: Pre-dose6.23 ± 82.03.51 ± 36.8NA ± NA13.5 ± 116.8—5.71 ± 44.24.32 ± NA2.06 ± NA4.09 ± NA3.99 ± NA4.03 ± 58.1NA ± NA17.8 ± NA
AR00426032, C2 D15: Pre-dose9.97 ± NA7.52 ± NA1.07 ± NA3.27 ± 65.11.74 ± NA4.23 ± 62.58.54 ± NA1.63 ± NA1.99 ± NA1.19 ± NA5.69 ± 57.01.33 ± NA3.74 ± NA
AR00426032 C3 D1: Pre-dose9.74 ± NA—NA ± NA6.15 ± NA—4.35 ± 42.34.50 ± NA1.09 ± NA——4.46 ± 70.21.73 ± NA—
AR00426032, C4 D1: Pre-dose7.10 ± NA————5.70 ± 11.85.43 ± NA2.78 ± NA——5.78 ± 83.0——
AR00426032, C5 D1: Pre-dose6.05 ± NA—————8.89 ± NA1.36 ± NA——6.11 ± 67.8——
AR00426032, EOTNA ± NANA ± NANA ± NANA ± NANA ± NA6.68 ± 80.13.77 ± NA1.48 ± NA3.65 ± NANA ± NA4.24 ± 85.5——
SecondaryPlasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II

LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II
Nanogram per milliliterPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg
Ribociclib, C1 D1: 1.5 hrs220 ± NA117 ± NA107 ± 40.6—230 ± 119.7185 ± NA784 ± NA
Ribociclib, C1 D1: 4 hrs213 ± NA84.5 ± NA205 ± 96.0—354 ± 58.5268 ± NA—
Ribociclib, C1 D8: Pre-dose77.4 ± NA32.3 ± NA30.7 ± 33.5—100 ± 49.980.5 ± NA127 ± NA
Ribociclib, C1 D15: Pre-dose98.4 ± NA28.2 ± NA30.7 ± 24.9—104 ± 54.264.7—
Ribociclib, C1 D15: 0.5 hr86.1 ± NA59.7 ± NA35.4 ± 66.6—179 ± 65.0——
Ribociclib, C1 D15: 1.5 hrs204 ± NA95.9 ± NA200 ± 240.3—508 ± 95.2——
Ribociclib, C1 D15: 2.5 hrs321 ± NA126 ± NA718 ± NA—627 ± 68.3393 ± NA—
Ribociclib, C1 D15: 4 hrs368 ± NA—341 ± 42.9—707 ± 62.2——
Ribociclib, C1 D15: 6 hrs434 ± NA109 ± NA239 ± 37.2—578 ± 55.9——
Ribociclib, C1 D15: 8 hrs311 ± NA83.6 ± NA182 ± 27.1—477 ± 55.2——
Ribociclib, C1 D16: 24 hrs94.0 ± NA25.6 ± NA52.7 ± 90.4—120 ± 64.991.8 ± NA—
Ribociclib, C1 D21: Pre-dose105 ± NA—102 ± NA—112 ± 75.869.9 ± NA115 ± NA
Ribociclib, C2 D1: Pre-doseNA ± NA19.5 ± NA1.59 ± NA1.07 ± NA7.00 ± 377.8—132 ± NA
Ribociclib, C2 D15: Pre-dose103 ± NA41.5 ± NA53.7 ± 51.236.0 ± NA107 ± 59.4113 ± NA102 ± NA
Ribociclib, C3 D1: Pre-dose1.16 ± NANA ± NA——4.06 ± 172.4——
Ribociclib, C4 D1: Pre-dose1.22 ± NA———1.59 ± 31.6——
Ribociclib, C5 D1: Pre-dose————2.16 ± 35.5——
Ribociclib, EOT1.94 ± NA60.3 ± NA1.49 ± NA45.8 ± NA29.0 ± 292.1—22.8 ± NA
LEQ803, C1 D1: 1.5 hrs57.1 ± NA70.2 ± NA68.2 ± 2.4—47.5 ± 97.459.0 ± NA63.6 ± NA
LEQ803, C1 D1: 4 hrs65.2 ± NA50.8 ± NA73.5 ± 20.4—81.1 ± 55.663.2 ± NA—
LEQ803, C1 D8: Pre-dose64.3 ± NA49.3 ± NA38.1 ± 9.1—53.7 ± 36.547.271.2
LEQ803, C1 D15: Pre-dose76.0 ± NA37.1 ± NA32.9 ± 25.7—55.1 ± 33.949.2 ± NA—
LEQ803, C1 D15: 0.5 hr75.5 ± NA39.5 ± NA32.1 ± 0.7—60.8 ± 36.9——
LEQ803, C1 D15: 1.5 hrs92.3 ± NA72.6 ± NA82.7 ± 0.7—112 ± 46.9——
LEQ803, C1 D15: 2.5 hrs130 ± NA92.5 ± NA126 ± NA—133 ± 45.4137 ± NA—
LEQ803, C1 D15: 4 hrs138 ± NA—140 ± 23.4—152 ± 31.2——
LEQ803, C1 D15: 6 hrs175 ± NA90.2 ± NA111 ± 27.6—145 ± 27.2——
LEQ803, C1 D15: 8 hrs135 ± NA79.8 ± NA95.2 ± 50.1—128 ± 27.6——
LEQ803, C1 D16: 24 hrs84.5 ± NA46.8 ± NA42.5 ± 13.8—63.1 ± 36.159.6 ± NA—
LEQ803, C1 D21: Pre-dose73.8 ± NA—43.7 ± NA—58.1 ± 39.152.9 ± NA80.2 ± NA
LEQ803, C2 D1: Pre-dose6.68 ± NA14.5 ± NA4.10 ± NA2.70 ± NA8.48 ± 154.5—80.8 ± NA
LEQ803, C2 D15: Pre-dose90.0 ± NA45.6 ± NA45.7 ± 6.828.0 ± NA58.3 ± 42.766.8 ± NA61.1 ± NA
LEQ803, C3 D1: Pre-dose7.88 ± NA2.75 ± NA——7.57 ± 61.4——
LEQ803, C4 D1: Pre-dose7.19 ± NA———5.72 ± 6.9——
LEQ803, C5 D1: Pre-dose————6.07 ± 28.9——
LEQ803, EOT10.4 ± NA69.3 ± NA5.06 ± 4.623.5 ± NA20.6 ± 152.2—31.2 ± NA
SecondaryPlasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II

BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mg
Infigratinib, C1 D1: 1.5 hrs15.0 ± NA
Infigratinib, C1 D8: Pre-dose2.67 ± NA
Infigratinib, C1 D15: Pre-dose2.49 ± NA
Infigratinib, C1 D15: 0.5 hr3.39 ± NA
Infigratinib, C1 D15: 1.5 hrs15.2 ± NA
Infigratinib, C1 D15: 2.5 hrs27.5 ± NA
Infigratinib, C1 D15: 4 hrs24.7 ± NA
Infigratinib, C1 D15: 6 hrs20.5 ± NA
Infigratinib, C1 D21: Pre-dose2.05 ± NA
Infigratinib, C2 D1: Pre-doseNA ± NA
Infigratinib, C2 D15: Pre-dose4.65 ± NA
Infigratinib, C3 D1: Pre-doseNA ± NA
Infigratinib, EOT2.42 ± NA
BHS697, C1 D1: 1.5 hrs4.83 ± NA
BHS697, C1 D8: Pre-dose2.17 ± NA
BHS697, C1 D15: Pre-dose1.64 ± NA
BHS697, C1 D15: 0.5 hr2.14 ± NA
BHS697, C1 D15: 1.5 hrs6.83 ± NA
BHS697, C1 D15: 2.5 hrs8.53 ± NA
BHS697, C1 D15: 4 hrs6.89 ± NA
BHS697, C1 D15: 6 hrs5.57 ± NA
BHS697, C1 D21: Pre-dose1.37 ± NA
BHS697, C2 D1: Pre-doseNA ± NA
BHS697, C2 D15: Pre-dose2.83 ± NA
BHS697, C3 D1: Pre-doseNA ± NA
BHS697, EOT1.69 ± NA
CQM157, C1 D1: 1.5 hrs13.0 ± NA
CQM157, C1 D8: Pre-dose14.1 ± NA
CQM157, C1 D15: Pre-dose11.1 ± NA
CQM157, C1 D15: 0.5 hr12.0 ± NA
CQM157, C1 D15: 1.5 hrs21.3 ± NA
CQM157, C1 D15: 2.5 hrs28.3 ± NA
CQM157, C1 D15: 4 hrs25.0 ± NA
CQM157, C1 D15: 6 hrs32.2 ± NA
CQM157, C1 D21: Pre-dose9.65 ± NA
CQM157, C2 D1: Pre-doseNA ± NA
CQM157, C2 D15: Pre-dose15.5 ± NA
CQM157, C3 D1: Pre-doseNA ± NA
CQM157, EOT11.9 ± NA
SecondaryPlasma Concentration for Capmatinib (INC): Part II

Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Capmatinib (INC): Part II
Nanogram per milliliterPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg
C1 D1: 1.5 hrs362 ± 268.63600 ± NA715 ± 133.2
C1 D8: Pre-dose74.3 ± 97.244.4 ± NA129 ± 49.4
C1 D15: Pre-dose89.3 ± 35.771.4 ± NA173 ± 41.2
C1 D15: 0.5 hr196 ± 103.81880 ± NA314 ± 49.0
C1 D15: 1.5 hrs636 ± 78.23670 ± NA1830 ± 38.3
C1 D15: 2.5 hrs545 ± 81.2—1530 ± 18.4
C1 D15: 4 hrs401 ± 17.31230 ± NA950 ± 39.1
C1 D15: 6 hrs157 ± 63.2264 ± NA487 ± 23.3
C1 D15: 8 hrs120 ± 50.0268 ± NA390 ± 10.5
C1 D16: 24 hrs79.6 ± 103.158.1 ± NA269 ± 68.7
C2 D1: Pre-dose151 ± 107.638.7 ± NA227 ± 42.0
C2 D15: Pre-dose65.2 ± 31.050.5 ± NA166 ± 80.9
C3 D1: Pre-dose114 ± 113.4—96.5 ± 17.9
C4 D1: Pre-dose——175 ± 44.8
C5 D1: Pre-dose—41.8 ± NA—
EOTNA ± NANA ± NA65.4 ± 155.0
SecondaryPlasma Concentration for Buparlisib (BKM): Part II

Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame:
C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration for Buparlisib (BKM): Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mg
C1 D1: 1.5 hrs213 ± NA213 ± NA
C1 D8: Pre-dose45.0 ± 75.2119 ± 3.6
C1 D15: Pre-dose49.7 ± 115.997.3 ± 16.2
C1 D15: 0.5 hr139 ± 13.4229 ± 21.5
C1 D15: 1.5 hrs266 ± 51.5312 ± 10.9
C1 D15: 2.5 hrs176 ± 42.2268 ± 11.9
C1 D15: 4 hrs115 ± 44.0235 ± 39.4
C1 D15: 6 hrs94.2 ± 40.0171 ± 26.4
C1 D15: 8 hrs87.4 ± 63.9111 ± 25.5
C1 D16: 24 hrs41.8 ± 82.9101 ± 1.4
C2 D1: Pre-dose54.7 ± 134.9110 ± 51.2
C2 D15: Pre-dose99.3 ± NA138 ± NA
C3 D1: Pre-dose81.2 ± NA—
C4 D1: Pre-dose73.2 ± NA—
C5 D1: Pre-dose122 ± NA—
EOT1.84 ± 53.4NA ± NA
SecondaryMaximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame:
C1 D15: 0.5 hour ± 10 (minutes) min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib3060 ± 58.82150 ± 54.62100 ± NA1600 ± 62.02890 ± NA2570 ± 23.0622 ± NA1960 ± NA1860 ± 32.12010 ± NA2030 ± 40.6—
Binimetinib386 ± 41.1221 ± 237.6413 ± NA515 ± 17.0797 ± NA858 ± 13.0261 ± NA520 ± NA313 ± 15.9584 ± NA489 ± 31.3291 ± NA
Binimetinib metabolite, AR0042603224.9 ± 92.218.1 ± 591.215.8 ± NA27.9 ± 85.622.6 ± NA47.1 ± 29.212.9 ± NA12.6 ± NA16.1 ± 151.919.4 ± NA23.7 ± 94.19.04 ± NA
Ribociclib——————434 ± NA126 ± NA428 ± 84.2282 ± NA753 ± 70.6597 ± NA
Ribociclib metabolite, LEQ803——————175 ± NA93.2 ± NA144 ± 19.267.5 ± NA156 ± 36.2138 ± NA
Infigratinib——27.5 ± NA—————————
Infigratinib metabolite, BHS697——8.53 ± NA—————————
Infigratinib metabolite, CQM157——32.2 ± NA—————————
Capmatinib———722 ± 85.33670 ± NA1920 ± 31.8——————
Buparlisib266 ± 51.5312 ± 10.9——————————
SecondaryTime to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Median · Hour
Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
HourPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib1.33 (0.58 to 1.50)1.54 (1.50 to 1.58)1.50 (1.50 to 1.50)1.50 (0.50 to 1.53)1.50 (1.50 to 1.50)1.50 (1.50 to 2.50)2.37 (2.37 to 2.37)1.47 (1.47 to 1.47)1.00 (0.50 to 1.50)1.50 (1.50 to 1.50)1.58 (0.63 to 6.17)—
Binimetinib1.50 (1.33 to 1.67)2.75 (1.50 to 4.00)1.50 (1.50 to 1.50)1.50 (0.50 to 1.58)1.50 (1.50 to 1.50)1.50 (1.50 to 2.50)1.38 (1.38 to 1.38)1.47 (1.47 to 1.47)1.50 (1.50 to 1.50)1.50 (1.50 to 1.50)1.58 (0.50 to 4.08)1.08 (1.08 to 1.08)
Binimetinib metabolite, AR004260321.50 (1.33 to 1.67)2.75 (1.50 to 4.00)1.50 (1.50 to 1.50)1.50 (1.50 to 1.58)4.00 (4.00 to 4.00)1.92 (1.50 to 2.50)1.38 (1.38 to 1.38)1.47 (1.47 to 1.47)1.50 (1.50 to 1.50)1.50 (1.50 to 1.50)1.65 (0.67 to 4.08)1.08 (1.08 to 1.08)
Ribociclib——————5.92 (5.92 to 5.92)2.45 (2.45 to 2.45)3.18 (2.33 to 4.03)1.50 (1.50 to 1.50)3.65 (1.50 to 6.00)0.50 (0.50 to 0.50)
Ribociclib metabolite, LEQ803——————5.92 (5.92 to 5.92)4.98 (4.98 to 4.98)3.18 (2.33 to 4.03)1.50 (1.50 to 1.50)4.12 (1.55 to 7.00)1.08 (1.08 to 1.08)
Infigratinib——2.50 (2.50 to 2.50)—————————
Infigratinib metabolite, BHS697——2.50 (2.50 to 2.50)—————————
Infigratinib metabolite, CQM157——5.75 (5.75 to 5.75)—————————
Capmatinib———1.53 (1.50 to 2.58)1.50 (1.50 to 1.50)1.50 (1.50 to 2.50)——————
Buparlisib1.50 (1.33 to 1.67)1.50 (1.50 to 1.50)——————————
SecondaryArea Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II
Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Geometric mean · Hour*nanogram per milliliter
Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II
Hour*nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib9080 ± 42.210100 ± 18.47420 ± NA4990 ± 42.610800 ± NA8570 ± 10.63490 ± NA6000 ± NA5740 ± 7.16200 ± NA11300 ± 41.1—
Binimetinib1580 ± 17.01220 ± 105.71260 ± NA2180 ± 29.43040 ± NA2760 ± 4.81700 ± NA1900 ± NA1140 ± 21.11740 ± NA2270 ± 29.51470 ± NA
Binimetinib metabolite, AR00426032116 ± 66.894.4 ± 222.242.0 ± NA124 ± 113.9135 ± NA182 ± 43.181.5 ± NA47.0 ± NA57.9 ± 128.566.9 ± NA115 ± 92.641.1 ± NA
Ribociclib——————5630 ± NA1650 ± NA3730 ± 62.52320 ± NA9230 ± 60.95960 ± NA
Ribociclib metabolite, LEQ803——————2770 ± NA1640 ± NA1900 ± 24.9930 ± NA2540 ± 31.32300 ± NA
Capmatinib———3070 ± 52.612200 ± NA8420 ± 22.0——————
Buparlisib2130 ± 54.63400 ± 18.5——————————
SecondaryElimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.

Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Mean · Hour
Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II
HourPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib3.75 ± 0.3025.89 ± 4.323.57 ± NA4.18 ± 1.853.41 ± NA3.96 ± 0.2334.27 ± NA3.75 ± NA4.32 ± 1.623.83 ± NA3.60 ± 0.711—
Binimetinib8.35 ± 3.523.48 ± 0.4841.60 ± NA10.3 ± 6.29—5.88 ± 2.775.84 ± NA3.82 ± NA5.38 ± 3.3910.9 ± NA4.13 ± 1.42—
Binimetinib metabolite, AR004260326.35 ± 1.214.14 ± 0.6831.59 ± NA7.95 ± 4.032.86 ± NA5.64 ± 2.49—4.34 ± NA6.24 ± 4.43—5.91 ± 3.00—
Ribociclib———————9.01 ± NA8.44 ± 2.2110.7 ± NA7.77 ± 1.9510.1 ± NA
Ribociclib metabolite, LEQ803———————19.9 ± NA14.1 ± 4.0419.2 ± NA16.0 ± 4.50—
Capmatinib———2.18 ± 0.05992.50 ± NA2.82 ± NA——————
Buparlisib15.4 ± 4.62———————————
SecondaryApparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Geometric mean · Liter per hour
Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II
Liter per hourPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib49.6 ± 42.144.7 ± 18.460.7 ± NA40.1 ± 42.618.6 ± NA23.4 ± 10.728.7 ± NA33.3 ± NA34.9 ± 6.932.2 ± NA19.5 ± 44.3—
Binimetinib28.5 ± 14.836.9 ± 105.735.6 ± NA20.8 ± 28.115.1 ± NA16.3 ± 5.017.4 ± NA15.8 ± NA26.5 ± 22.625.9 ± NA19.9 ± 29.2—
Ribociclib———————243 ± NA161 ± 61.1173 ± NA62.4 ± 58.599.3 ± NA
Capmatinib———65.9 ± 52.224.8 ± NA45.7 ± 24.4——————
Buparlisib28.2 ± 53.623.2 ± NA——————————
SecondaryApparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.

Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II
LiterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib268 ± 45.4324 ± 69.8313 ± NA226 ± 92.991.7 ± NA133 ± 13.5177 ± NA180 ± NA210 ± 32.3178 ± NA99.3 ± 46.0—
Binimetinib324 ± 58.3185 ± 83.482.5 ± NA244 ± 75.9—125 ± 56.1147 ± NA86.8 ± NA184 ± 111.8406 ± NA113 ± 48.5—
Ribociclib———————3160 ± NA1930 ± 30.52660 ± NA677 ± 65.01440 ± NA
Capmatinib———190 ± 30.389.5 ± NA233 ± NA——————
Buparlisib604 ± 17.4———————————
SecondaryLast Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame:
C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour
Reported as:
Geometric mean · Nanogram per milliliter
Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib11.3 ± 45.325.1 ± 2066.86.76 ± NA15.9 ± 315.95.20 ± NA15.0 ± 20.910.7 ± NA7.85 ± NA10.8 ± 106.110.5 ± NA33.7 ± 254.3—
Binimetinib44.1 ± 19.130.2 ± 59.255.8 ± NA63.2 ± 64.017.6 ± NA55.9 ± 54.078.3 ± NA29.8 ± NA23.1 ± 5.247.9 ± NA58.7 ± 60.240.5 ± NA
Binimetinib metabolite, AR004260323.99 ± 61.82.92 ± 159.31.82 ± NA5.57 ± 130.21.44 ± NA4.75 ± 25.46.53 ± NA1.08 ± NA2.31 ± 47.83.54 ± NA4.68 ± 92.31.56 ± NA
Ribociclib——————94.0 ± NA25.6 ± NA52.7 ± 90.434.9 ± NA147 ± 71.891.8 ± NA
Ribociclib metabolite, LEQ803——————84.5 ± NA46.8 ± NA42.5 ± 13.822.8 ± NA73.2 ± 49.659.6 ± NA
Infigratinib——20.5 ± NA—————————
Infigratinib metabolite, BHS697——5.57 ± NA—————————
Infigratinib metabolite, CQM157——32.2 ± NA—————————
Capmatinib———79.6 ± 103.158.1 ± NA269 ± 68.7——————
Buparlisib41.8 ± 82.9101 ± 1.4——————————
SecondaryMeasured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Time frame:
C1 D15: at the end of a dosing interval at steady-state (24 hour ± 2 hour), taken directly before next administration
Reported as:
Geometric mean · Nanogram per milliliter
Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II
Nanogram per milliliterPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 60 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Buparlisib 90 mgPart II: Encorafenib 450 mg/ Binimetinib 45 mg + Infigratinib 75 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 200 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mgPart II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mgPart II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mgPart II: Encorafenib 300 mg/Binimetinib 30 mg + Ribociclib 600 mg
Encorafenib11.2 ± 106.318.6 ± 159.47.74 ± NA11.6 ± 51.37.95 ± NA13.5 ± 35.09.28 ± NA10.3 ± NA7.75 ± 37.310.4 ± NA21.7 ± 185.4—
Binimetinib32.0 ± 17.139.1 ± 57.433.9 ± NA81.2 ± 47.547.3 ± NA50.9 ± 34.454.3 ± NA28.3 ± NA21.1 ± 23.731.5 ± NA51.0 ± 76.136.2 ± NA
Binimetinib metabolite, AR004260323.14 ± 74.53.80 ± 111.91.21 ± NA8.22 ± 84.64.36 ± NA5.45 ± 42.24.16 ± NANA ± NA3.81 ± NA1.72 ± NA4.34 ± 79.91.09 ± NA
Ribociclib——————98.4 ± NA28.2 ± NA30.7 ± 24.936.4 ± NA104 ± 54.264.7 ± NA
Ribociclib metabolite, LEQ803——————76.0 ± NA37.1 ± NA32.9 ± 25.722.8 ± NA55.1 ± 33.949.2 ± NA
Infigratinib——2.49 ± NA—————————
Infigratinib metabolite, BHS697——1.64 ± NA—————————
Infigratinib metabolite, CQM157——11.1 ± NA—————————
Capmatinib———83.9 ± 34.071.4 ± NA173 ± 41.2——————
Buparlisib49.7 ± 115.997.3 ± 16.2——————————

Adverse events

Collected over Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks and for Part II was 97.0 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I: Encorafenib + Binimetinib (Naive)20/75 (26.7%)47/75 (62.7%)75/75 (100%)
Part I: Encorafenib + Binimetinib (Non-naive)29/83 (34.9%)37/83 (44.6%)73/83 (88%)
Part II: Encorafenib + Binimetinib + Ribociclib28/38 (73.7%)19/38 (50%)33/38 (86.8%)
Part II: Encorafenib + Binimetinib + Infigratinib1/1 (100%)0/1 (0%)0/1 (0%)
Part II: Encorafenib + Binimetinib + Capmatinib8/13 (61.5%)6/13 (46.2%)11/13 (84.6%)
Part II: Encorafenib + Binimetinib + Buparlisib4/6 (66.7%)4/6 (66.7%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Back painMusculoskeletal and connective tissue disorders1/750/831/380/10/131/6
Pain in extremityMusculoskeletal and connective tissue disorders1/750/831/380/10/131/6
SeizureNervous system disorders2/750/830/380/10/131/6
DeliriumPsychiatric disorders1/751/830/380/10/131/6
Pelvic painReproductive system and breast disorders0/750/830/380/10/131/6
Pleural effusionRespiratory, thoracic and mediastinal disorders0/750/830/380/10/131/6
AnaemiaBlood and lymphatic system disorders3/751/832/380/11/130/6
Cardiac arrestCardiac disorders0/750/830/380/11/130/6
Cardiac failureCardiac disorders0/750/830/380/11/130/6
ColitisGastrointestinal disorders0/751/830/380/11/130/6
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPart I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + Buparlisib
Blood creatine phosphokinase increasedInvestigations38/7510/835/380/12/130/6
AnaemiaBlood and lymphatic system disorders28/7516/8310/380/13/133/6
DiarrhoeaGastrointestinal disorders33/7525/839/380/12/131/6
FatigueGeneral disorders31/7527/836/380/11/130/6
NauseaGastrointestinal disorders30/7533/8315/380/12/132/6
ArthralgiaMusculoskeletal and connective tissue disorders26/7515/832/380/10/131/6
PyrexiaGeneral disorders13/7516/837/380/10/132/6
Aspartate aminotransferase increasedInvestigations9/756/834/380/10/132/6
RetinopathyEye disorders22/7510/830/380/10/130/6
ConstipationGastrointestinal disorders22/7513/835/380/11/131/6

Baseline characteristics

Analysis population: participants who were treated with at least 1 dose (partial or full) of encorafenib or binimetinib in Part I and at least 1 dose of encorafenib or binimetinib or the assigned third agent following the assignment of the triple combination treatment in Part II. Parts I and II participants are not exclusive. To avoid risk of identification of participant, baseline measure data is not disclosed for reporting arm including Infigratinib and reported under category- Not Disclosed.

Age, Customized
Age, Customized(Participants)Part I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + BuparlisibTotal
Part I — 18-44 years1424000038
Part I — 45-64 years4337000080
Part I — 65 years and over1822000040
Part I — Not disclosed0000000
Part II — 18-44 years00900110
Part II — 45-64 years001907430
Part II — 65 years and over001006117
Part II — Not disclosed0001001
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + BuparlisibTotal
Part I — Female2839000067
Part I — Male4744000091
Part I — Not Disclosed0000000
Part II — Female002205128
Part II — Male001608529
Part II — Not Disclosed0001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + BuparlisibTotal
Race: Part I — Caucasian74820000156
Race: Part I — Asian1100002
Race: Part I — Not Disclosed0000000
Race: Part II — Caucasian0037013656
Race: Part II — Asian0010001
Race: Part II — Not Disclosed0001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part I: Encorafenib + Binimetinib (Naive)Part I: Encorafenib + Binimetinib (Non-naive)Part II: Encorafenib + Binimetinib + RibociclibPart II: Encorafenib + Binimetinib + InfigratinibPart II: Encorafenib + Binimetinib + CapmatinibPart II: Encorafenib + Binimetinib + BuparlisibTotal
Ethnicity: Part I — Hispanic or Latino37000010
Ethnicity: Part I — Not Hispanic or Latino72760000148
Ethnicity: Part I — Not Disclosed0000000
Ethnicity: Part II — Hispanic or Latino0010001
Ethnicity: Part II — Not Hispanic or Latino0037013656
Ethnicity: Part II — Not Disclosed0001001
08

Study locations

32 sites
  • University of California Los Angeles
    Los Angeles, California 90024, United States
  • Cancer Care Center
    Los Angeles, California 90095, United States
  • Doris Stein Research Center Building
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
    Los Angeles, California 90095, United States
  • UCLA Dermatology Clinic
    Los Angeles, California 90095, United States
  • UCLA Oncology Center
    Los Angeles, California 90095, United States
  • UCLA Radiology
    Los Angeles, California 90095, United States
  • Memorial Sloan Kettering Cancer Center Attn: Geny O'neill
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center Inpatient Hospital & Main Campus
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center- Outpatient Clinic
    New York, New York 10065, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97201, United States
  • OHSU Center for Health and Healing 2
    Portland, Oregon 97239, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • OHSU Research Pharmacy Services
    Portland, Oregon 97239, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • East St Kilda Eye Clinic
    Melbourne, Victoria 3183, Australia
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
  • Sir Mortimer B. Davis-Jewish General Hospital
    Monteral, Quebec H3T 1E2, Canada
  • University Clinic Heidelberg PPDS
    Heidelberg, Baden-württemberg 69120, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Bayern 97080, Germany
  • Uniklinik Köln
    Köln, 50937, Germany
  • Städtisches Klinikum München
    Muenchen, 80337, Germany
  • Universitätsklinikum Würzburg
    Wuerzburg, 97080, Germany
  • Azienda Ospedaliera Monaldi
    Napoli, Campania 80131, Italy
  • U.O.C. Oncologia Medica e Terapie Innovative Dipartimento di Melanoma IRCCS Fondazione G. Pascale
    Napoli, 80131, Italy
  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
    Amsterdam, 1066 CX, Netherlands
  • Hospital Universitario Vall d'Hebrón - PPDS
    Barcelona Cataluna, Barcelona 08035, Spain
  • Universitätsspital Zürich
    Zurich Flughafen, 8058, Switzerland
  • Churchill Hospital
    Oxford, OX2 7JL, United Kingdom
09

References and documents

Publications

  • Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouet-Astrie C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 Oct;20(10):2049-2060. doi: 10.1158/1535-7163.MCT-20-1126. Epub 2021 Aug 10. PubMed 34376578 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jan 2023, 101 months.

Results were first posted in Mar 2024, 1 year 1 month after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 101 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2014
First posted
Jun 9, 2014
StartActual
Jul 23, 2014
Primary completionActual
Jan 10, 2023
CompletionActual
Jan 10, 2023
Results first posted
Mar 5, 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02159066
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 9, 2014
Start date
Jul 23, 2014
Primary completion
Jan 10, 2023
Completion
Jan 10, 2023
Results posted
Mar 5, 2024
Last update
Mar 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Binimetinib · Ribociclib · Infigratinib · Buparlisib · Capmatinib

Start the discussion